Kyverna Therapeutics Inc (KYTX)

NASD · Healthcare · Biotechnology · USA

Kyverna Therapeutics Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.

Kyverna Therapeutics develops cell therapies for autoimmune diseases. Its lead program, mivocabtagene autoleucel, is an autologous CAR T-cell therapy that depletes CD19-expressing B cells. The company currently evaluates this therapy in clinical trials for stiff person syndrome and generalized myasthenia gravis.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Kyverna Therapeutics Inc stock.

Our verdict on KYTX

Not valued: We cannot value this company yet.

ETFs with the most weight in KYTX

17 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than KYTX in Biotechnology

129 more in this industry show a wider margin of safety.

Is KYTX undervalued or overvalued?

We do not publish a verdict on KYTX yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.

What is the intrinsic value of KYTX?

We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.